Associate Professor James Wilmott is the Senior Scientist at the Translational Research Laboratory of the Melanoma Institute Australia, based at the University of Sydney. Associate Professor Wilmott has extensive experience leading translational biomarker programs as part of large international oncology trials, with work published in Lancet Oncology, Nature, Cancer Cell, and Clinical Cancer Research. His research applies a multi-omic approach, combining genomic, transcriptomic, and spatial biology to identify mechanisms of immunotherapy response and resistance.

He is the Principal Investigator of the Personalised Immunotherapy Program (PIP), which is conducting a multi-cancer prospective biomarker testing program designed to implement and validate the use of multi-omics and machine learning models to inform the precision use of immunotherapies. His current work focuses on the implementation of precision oncology within clinical trials in oncology clinics, as well as a biological program aimed at identifying the mechanisms associated with multi-omic biomarker results.